A new treatment is bound to help men who had prostate cancer, and it persisted or recurred. Anti-androgen therapy after a radical prostatectomy can boost men overall survival rates compared with those who only used salvage radiation treatment. The new study presents the dual treatment as being one of the best solutions, which also decreases the prevalence of metastatic illness.
In a new study, 760 men who have prostate cancer were asked to undergo salvage radiation therapy. Scientists revealed that those patients who also received bicalutamide on a daily basis for 24 months had a 23% decreased risk of death compared to those who only got a daily placebo.
The placebo group and the bicalutamide one included 376 and 384, respectively. Bicalutamide patients were asked to take a 150-mg pill every day. In both groups, about 258 participants managed to stick to the plan, completing their therapy treatment. The participants who survived had an average follow-up of approximately 13 years.
William U. Shipley, MD, of Massachusetts General Hospital in Boston, together with his colleagues has reported that the actual survival rate at 12 years was estimated at 76.3% in the group being treated with bicalutamide and 71.3% in the placebo group. Their study was published in The New England Journal of Medicine.
The combined prevalence of metastatic prostate cancer at 12 years was estimated at 14.5% in the bicalutamide group while the placebo group registered 23.0% mortality. The 12-year relative incidence of cancer-linked death was 5.8% in the bicalutamide group and 13.4% of the placebo participants.
Both groups showed signs of similar prevalence regarding late adverse symptoms linked to radiation therapy. Researchers indicated that after this trial was developed, gonadotropin-releasing hormone (GnRH) antagonists have replaced bicalutamide, becoming the first-choice hormonal therapy used with radiation therapy.
Other surveys which involved participants with non-metastatic disease proved that excessive use of GnRH agonists and bicalutamide had similar methodical anti-cancer effectiveness. Scientists noted that the trial developed by them holds the principal evidence suggesting that overused hormone-based therapy added to salvage radiation therapy was linked to significantly lower rates of prostate cancer metastases and also death.
Dr. Shipley together with his colleagues has calculated that twenty patients need to be treated with bicalutamide to prohibit the occurrence of one death over a 12-year time span.
Image courtesy of: wikipedia